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Neutralization of HIV by antibodies is gener-
ally attributed to antibody occupancy of the 
envelope trimers and interference with viral 
attachment to host cell receptors or entry, but 
the precise underlying molecular mechanisms 
leading to neutralization by most neutralizing 
antibodies identified to date await clarification 
(Zwick and Burton, 2007). A considerable ef-
fort in the development of HIV vaccines has 
been directed toward eliciting neutralizing an-
tibody responses that mimic activities of the 
membrane-proximal external region (MPER)–
specific mAbs 2F5 and 4E10. Information on 
the structural composition of the MPER has 
broadened in recent years, and studies of epi-
tope accessibility have highlighted the possi-
bility that neutralization by MPER-specific 
antibodies may require the recognition of their 
epitopes in the context of membrane lipids 
(Cardoso et al., 2007; Montero et al., 2008; 
Alam et al., 2009) and may depend on the for-
mation of the prehairpin intermediate state 
during viral entry (Frey et al., 2008, 2010; Alam 
et al., 2009). Whether these antibodies can act 
on free virus in the absence of target cells and 
receptor engagement remains uncertain, and 
thus the precise window of action of these an-
tibodies, their modes of epitope recognition, 
and a detailed mechanism of neutralization still 
await further definition.
Our understanding of the biochemical ac-
tivity and biological function of neutralizing 
antibodies is shaped by studies that have as-
sessed the initial interaction between antibodies 
and HIV and their capacity to block virus entry 
in relatively short-term experimental settings 
but have left the fate of neutralized virions 
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Interference with virus entry is known to be the principle mechanism of HIV neutralization 
by antibodies, including 2F5 and 4E10, which bind to the membrane-proximal external 
region (MPER) of the gp41 envelope protein. However, to date, the precise molecular 
events underlying neutralization by MPER-specific antibodies remain incompletely under-
stood. In this study, we investigated the capacity of these antibodies to irrevocably sterilize 
HIV virions. Long-term effects of antibodies on virions can differ, rendering neutralization 
either reversible or irreversible. MPER-specific antibodies irreversibly neutralize virions, and 
this capacity is associated with induction of gp120 shedding. Both processes have similar 
thermodynamic properties and slow kinetics requiring several hours. Antibodies directed to 
the CD4 binding site, V3 loop, and the MPER can induce gp120 shedding, and shedding 
activity is detected with high frequency in plasma from patients infected with divergent 
genetic HIV-1 subtypes. Importantly, as we show in this study, induction of gp120 shedding 
is closely associated with MPER antibody inhibition, constituting either a primary event 
leading to virion neutralization or representing an immediate consequence thereof, and 
thus needs to be factored into the mechanistic processes underlying their activity.
© 2011 Ruprecht et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first 
six months after the publication date (see http://www.rupress.org/terms). After 
six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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Figure 1. Kinetics and reversibility of HIV neutralization. (A) Time dependence of neutralization activity was probed by preincubating serial dilu-
tions of mAbs b12, 2G12, 2F5, and 4E10 with 11 different R5 and X4 pseudoviruses (Tables S1 and S2) for 1 h or overnight (o/n; 16–18 h) at 37°C before 
infection of TZM-bl target cells. The 50% inhibitory concentration (IC50) for each mAb/treatment condition is depicted. IC50 values were derived from sig-
moid dose–response curve fits of pooled data of two to three independent experiments. The number of viruses not neutralized (NN) at the highest mAb concen-
tration probed is indicated on top of each antibody panel. (B) Decay of HIV upon long-term exposure to 37°C. A fixed virus input (JR-FL enveloped-pseudotyped 
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induced gp120 shedding upon prolonged contact with the 
virus, rendering neutralization irreversible. The kinetic and 
thermodynamic requirements of the shedding process were 
virtually identical to those of neutralization, identifying gp120 
shedding as a key process associated with HIV neutralization 
by MPER antibodies.
RESULTS AND DISCUSSION
Kinetics of HIV neutralization
To study the effects of long-term interaction of HIV with 
neutralizing antibodies, we compared short- (1 h) and long-
term (overnight; 16–18 h) inhibitory activity of the neutraliz-
ing antibodies b12 (gp120 CD4 binding site [CD4bs] specific; 
Barbas et al., 1992), 2G12 (gp120 carbohydrate specific; 
Trkola et al., 1996), and the gp41 MPER–specific antibodies 
2F5 (Muster et al., 1993) and 4E10 (Stiegler et al., 2001; 
Zwick et al., 2001) against a panel of envelope-pseudotyped 
luciferase reporter viruses (Fig. 1 A and Table S1). Although 
long-term coincubation of virus with mAb 2G12 showed no 
or only modest increases in neutralization, prolonged coincu-
bation markedly improved the neutralizing capacity of 2F5, 
4E10, and b12. As noted previously (Binley et al., 2004), neu-
tralization activity of MPER mAbs, in particular, increased by 
more than one order of magnitude upon extended interaction 
with several of the tested isolates. We ascertained that these 
increases in inhibitory activity upon prolonged interaction 
with the virus were a consequence of the antibodies’ action 
and not a result of spontaneous decay of virions. Although 
HIV infectivity decreases upon prolonged incubation at 37°C, 
largely unexplored. HIV neutralization is commonly assessed 
under conditions that do not allow discrimination between 
actions of the neutralizing antibody on the free virus and ac-
tions after receptor engagement, as antibody is usually present 
throughout all steps, including preincubation and infection. 
In this study, we specifically investigated the actions of MPER 
mAbs on virions in the absence of target cell interactions to 
determine whether and to what extent this type of antibody 
can contribute to clearance of virus particles in vivo.
Whether neutralization causes an irreversible deactivation 
of HIV or whether virions can regain activity after antibody 
dissociation may also significantly impact the in vivo efficacy 
of a given antibody. In vivo virions can persist for extended 
periods of time before encountering appropriate target cells 
or being cleared by phagocytes. The sequestration of HIV by 
DCs is well documented in this respect. Trapped by DCs, the 
virus can remain infectious for several days and efficiently 
be transferred to CD4+ T cells (Turville et al., 2004; Yu 
et al., 2008). Should neutralization be reversible, trafficking of 
antibody-opsonized virus to intracellular compartments or 
anatomical sites with lower antibody concentration could 
potentially lead to antibody dissociation and reconstitute 
the virus’s infectivity. Achieving irreversible neutralization 
is thus clearly desirable for both natural and vaccine-elicited 
immune responses.
In this study, we aimed to obtain insight into the long-
term effect of broadly neutralizing antibodies on cell-free 
HIV particles and their capacity to irreversibly inactivate the 
virus. Most notably, the MPER-specific antibodies potently 
virus; 3,000 TCID50/well in culture medium; no mAbs) was incubated for the indicated time periods at 37°C before infection of TZM-bl target cells, and 
virus infectivity was monitored by luciferase reporter gene production 72 h after infection. Relative light units (RLU) measured per well are depicted. Val-
ues are means of 15 replicas, and error bars indicate SEM. One out of five independent experiments is shown. (C) mAb neutralization is constant over a 
wide range of viral input. Serial dilutions of JR-FL envelope-pseudotyped virus were pretreated for 1 h at 37°C with a fixed concentration of each mAb at 
concentrations that typically yield neutralization below 70% (0.02 µg/ml mAb b12, 1 µg/ml 2G12, 1.5 µg/ml 2F5, and 7 µg/ml 4E10). In parallel, for each 
virus dilution, a mock treatment (incubation without mAb) was performed. The viral infectivity of each virus dilution (relative light units of mock-treated 
sample, measured 72 h after infection) is plotted on the x axis. The y axis indicates the neutralization each antibody achieved at the respective virus input. 
Error bars indicate SEM. (D) Enhanced mAb neutralization over prolonged incubation is not caused by spontaneous virus decay. In experiments depicted 
by red symbols, virus input and mAb concentration were kept constant, and only incubation time was varied. In experiments depicted by black symbols, 
incubation time (1 h) and mAb concentration were kept constant, and only virus input was varied. mAbs were probed at concentrations that typically 
yield neutralization below 70% (0.02 µg/ml mAb b12, 1 µg/ml 2G12, 1.5 µg/ml 2F5, and 7 µg/ml 4E10). For the red symbols, JR-FL pseudo virus was pre-
treated with the respective mAbs for the indicated times at 37°C. In parallel, for each time point, a mock control (incubation in medium without mAb) was 
performed. The viral infectivity measured for the mock treatment is plotted on the x axis for each time point (relative light units, measured 72 h after 
TZM-bl cell infection). The y axis indicates the neutralization each antibody achieved at after the respective preincubation time. For the black symbols, JR-
FL pseudo virus was titrated and preincubated for 1 h at 37°C with the respective mAbs or a mock control (incubation in medium without mAb). The viral 
infectivity of the mock-treated samples is plotted on the x axis for the respective virus input. The y axis indicates the neutralization activity each antibody 
achieved at the respective virus input. Data points are means of 20 replicates. Error bars indicate SEM. One of two independent experiments is shown.  
(E) Increases in inhibitory activity upon prolonged interaction with the virus are a consequence of the antibodies’ action. Envelope-pseudotyped JR-FL 
was incubated with serial dilutions of b12, 2G12, 2F5, and 4E10 or left untreated for either 1 or 18 h. Alternatively, virus was left untreated for 17 h be-
fore being treated for 1 h with neutralizing antibodies. Pretreated virus was then added to TZM-bl cells, and virus infectivity was measured by luciferase 
reporter gene production 72 h after infection. The 50% inhibitory concentration (IC50) for each mAb/treatment condition is depicted. IC50 values were 
derived from sigmoid dose–response curve fits of pooled data of three independent experiments. (F) Time of addition experiments were conducted to 
probe the kinetics of mAb neutralization. Antibody concentrations were chosen to yield neutralization of 70% after 20 h of preincubation to allow for 
the monitoring of increases in neutralization activity over time. 0.03 µg/ml b12, 12 µg/ml 2G12, 2.5 µg/ml 2F5, 8.5 µg/ml 4E10, and 0.1 µg/ml CD4-IgG2 
were incubated with JR-FL pseudovirus for the indicated time periods at 37°C. Percent neutralization of virus infectivity on TZM-bl cells was calculated in 
reference to the respective mock-treated virus control of each time point. One of six independent experiments is shown. Data points depict means and 
SEM of duplicate measurements.
 
442 HIV gp120 shedding by MPER antibodies | Ruprecht et al.
a reversible event. To probe reversibility, we generated JR-FL 
pseudovirus that coexpresses mouse CD4, allowing rapid 
separation of virions and unbound antibodies using magnetic 
beads (Fig. 2). We subjected virions to neutralizing antibodies, 
followed by the opportunity for antibody dissociation and re-
moval of unbound antibody (treatment A). Two sets of controls 
determined the extent of neutralization by antibody-treated 
virus without dissociation (treatment B) and the maximal in-
hibitory activity without removal of antibody (treatment C). 
Most interestingly, neutralization by the MPER mAbs proved 
to be irreversible. Removal of excess antibody (treatment B) 
led to only a small reduction in 2F5 and 4E10 neutralization 
activity (24% and 22%, respectively), likely accounting for 
ongoing neutralization when mAbs were not removed. Impor-
tantly, MPER mAb–opsonized virus remained stably neutral-
ized over the 11-h dissociation period (treatment A). Virtually 
complete irreversibility of neutralization was observed for 
mAb b12, as the virus remained neutralized throughout the 
observation period. In contrast, 2G12 immediately lost the 
majority of its neutralization activity once excess antibody 
was removed (treatment B), and the virus was able to regain 
its infectivity almost completely (treatment A), indicating that 
neutralization by 2G12 is reversible and steered by a high off 
rate in binding to the HIV envelope.
Neutralizing antibodies induce gp120 shedding
Having established that certain neutralizing antibodies irrevo-
cably inactivate HIV, we investigated plausible mechanisms of 
this process. To probe whether neutralizing antibodies induce 
conformational changes in the envelope trimer that irrevoca-
bly perturb functionality, we assessed the capacity of opso-
nized JR-FL pseudovirus to bind to 3D6, an antibody specific 
for the immunodominant (cluster I) region in gp41 inaccessi-
ble on intact envelope trimers (Sattentau et al., 1995; Finnegan 
et al., 2002). Soluble CD4 (sCD4) treatment is known to induce 
conformational changes within gp120 (Kwong et al., 1998) and 
to cause shedding of gp120 (Moore et al., 1990), both of 
which lead to exposure of otherwise hidden domains in gp41 
(Sattentau et al., 1995; Finnegan et al., 2002). In line with this, 
we observed a strong increase in 3D6 binding (7.5-fold) to 
virions upon sCD4 treatment (Fig. 3 A). Most strikingly, 
treatment with mAbs 2F5 or 4E10 also led to a pronounced 
exposure of cluster I epitopes on virions, whereas the gp41-
targeting inhibitor T-20 had no such effect, suggesting that 
MPER mAbs either induced gp120 shedding or caused an 
extensive structural reorganization of gp120 and gp41 mole-
cules within the trimer.
To directly probe for gp120 shedding, JR-FL pseudovirus 
was first treated with neutralizing antibodies. After bead immo-
bilization (via coexpressed mouse CD4), unbound antibody and 
potentially shed gp120 was removed, and virus-associated gp120 
content was quantified (Fig. 3 B). Comparing mock-treated with 
CD4-IgG2 (tetrameric CD4 Ig)– and neutralizing mAb–treated 
JR-FL pseudovirus, we observed remarkable potency of the 
MPER mAbs to induce gp120 shedding upon long-term inter-
action with the virus. Likewise, antibody b12 induced gp120 
this loss is moderate (<1 log within 24 h; Fig. 1 B). To study 
HIV neutralization by mAbs in vitro, antibodies are com-
monly supplied in stoichiometric excess over the viral target, 
allowing robust assessment of neutralization activity over a 
wide range of virus input. This was also true in our assay setup, 
in which we measured the virtually identical neutralization 
capacity of b12, 2G12, 2F5, and 4E10 over a >2-log range of 
virus inputs (Fig. 1 C). Assessment of mAb-independent 
decrease in virus infectivity and the enhanced mAb neutral-
ization activity during long-term incubation in parallel con-
firmed that the moderate loss observed in infectivity does not 
impact the assessment of neutralization activity in our experi-
mental setup (Fig. 1 D). Increases in the neutralization capac-
ity of 2F5, 4E10, and b12 upon prolonged incubation are thus 
caused by the antibodies’ action. However, under the same 
conditions, long-term treatment by 2G12 induced no equiva-
lent improvement in neutralization. To formally exclude the 
influence of virus decay, we performed a series of further 
control experiments (Fig. 1 E) in which virus was subjected 
to a 1- (condition 1) and 18-h (condition 2) preincubation 
with mAbs at 37°C. Condition 3 controlled for viral decay 
during the 18-h incubation by incubating the virus, in ab-
sence of mAbs, for 17 h at 37°C, followed by a 1-h mAb 
treatment. The latter confirmed that viral decay had no gen-
eral influence on neutralization activity, as conditions 1 and 3 
resulted in identical inhibitory activity.
We next defined the specific kinetics of mAb binding to 
virions (Fig. S1, A and B) and neutralization (Fig. 1 F) in time 
of addition experiments. To monitor increases in neutraliza-
tion activity over time, fixed antibody doses that typically 
yield 70% neutralization of JR-FL pseudovirus only after 
20-h preincubation were chosen. 2G12 rapidly bound to vi-
rions and instantly neutralized, but this activity only moder-
ately improved upon sustained treatment, suggesting that easy 
access to its well exposed glycan epitope fosters a compara-
tively fast and efficient binding (Fig. S1 B) and neutralization 
reaction. In contrast, both binding and neutralization by b12 
and the MPER mAbs gradually and substantially increased 
over time. The latter clarifies a longstanding debate as it con-
firms that 2F5 and 4E10 can access the MPER on virions 
before receptor engagement. Yet, in agreement with previous 
studies, the slow kinetics of binding and neutralization (>7 h; 
Fig. 1 F and Fig. S1) suggest that access to the MPER epitope 
is highly restricted (Binley et al., 2003; Frey et al., 2008). Inef-
fective binding could be a consequence of steric interference 
of antibody binding to the MPER epitope, which is thought 
to be partially buried in the viral membrane. In fact, efficient 
MPER mAb binding may depend on a prior association of 
the mAbs with the viral membrane (Cardoso et al., 2007; 
Alam et al., 2009; Buzon et al., 2010; Frey et al., 2010). Alter-
natively, envelope conformations that expose the MPER may 
only infrequently be formed.
Is neutralization by antibodies reversible?
One specific purpose of studying long-term effects of anti-
body action was to determine whether neutralization of HIV is 
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(Moore et al., 1990; McDougal et al., 
1996; Poignard et al., 1996). Although 
sCD4 has been long known to induce 
dissociation of gp120 (Moore et al., 
1990), to what extent shedding contrib-
utes to sCD4 inhibitory activity has 
never been fully unraveled as these pro-
cesses can differ in concentration and 
temperature dependence (McDougal 
et al., 1996; Chertova et al., 2002). 
Importantly, sCD4 mediates weaker 
shedding and neutralization of PBMC-
derived viruses than T cell line–adapted 
strains, likely accounting for the failure of 
recombinant CD4-based therapies (Daar 
et al., 1990; Moore et al., 1992; Orloff  
et al., 1993). Previous investigations into 
shedding as a potential mechanism for 
antibody neutralization of HIV yielded 
inconclusive results (Moore et al., 1990; 
McDougal et al., 1996; Poignard et al., 
1996). MPER-specific antibodies had 
not been investigated, and neutralizing 
CD4bs mAbs (including b12) were 
reported to lack shedding activity 
(McDougal et al., 1996; Poignard et al., 
1996). Although several mAbs directed 
to other domains in gp120 were found 
to partially dissociate the envelope of 
T cell line–adapted strains and a direct 
association between antibody neutral-
ization and gp120 shedding was inferred 
to, a causal link between these modes of 
action was not formally experimentally established (Poignard 
et al., 1996). Thus, the relevance of shedding as a mechanism of 
HIV neutralization by antibodies has remained to some extent 
uncertain. The potential in vivo significance of the shedding pro-
cess was equally unclear as activity against primary viruses was 
not confirmed (McDougal et al., 1996; Poignard et al., 1996).
shedding, whereas 2G12 had no such effect. Of note, in contrast 
to CD4-IgG2, which induced rapid shedding, short-term in-
cubation with the probed neutralizing mAbs had only 
minimal influence on gp120 dissociation (Fig. 3 B). The latter 
may account for the difficulty of earlier studies to identify induc-
tion of gp120 shedding by CD4bs antibodies, including b12 
Figure 2. Reversibility of HIV neutraliza-
tion. (A and B) Reversibility of neutralization 
was probed as depicted in the flow chart. 
Antibody concentrations were chosen to yield 
neutralization activities of 90% after 11 h 
of preincubation to allow for monitoring de-
creases in neutralization activity after the 
dissociation step. JR-FL neutralization by  
0.1 µg/ml b12, 15 µg/ml 2G12, 11.4 µg/ml 2F5, 
and 45 µg/ml 4E10 was probed under the 
indicated treatment conditions: after antibody 
dissociation (treatment A), neutralization 
without dissociation (treatment B), and with-
out removal of antibody (treatment C). Means 
and SEM of triplicates measurements of one 
of three independent experiments are shown. 
Abs, antibodies.
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period and compared these activities with those in a conven-
tional assay format, in which antibody was present through-
out (Fig. 3 C and Fig. S1, C and D). The results were strikingly 
clear; neither 2F5 nor 4E10 were capable of neutralizing JR-FL 
when only present during the 1-h preincubation period. They 
only neutralized when either was allowed to interact with the 
cell free virus for prolonged periods or when present during 
both preincubation and the entire infection period. These 
data confirm that neutralization of free virions by MPER anti-
bodies in the absence of receptor interactions requires pro-
longed interaction of the mAbs with the HIV particle and 
thus follows the reactivity pattern observed for MPER-induced 
gp120 shedding.
Our finding that MPER mAbs induce gp120 shedding is 
of obvious interest not only as it provides a long sought for 
insight into their mechanism of action but also as this process 
leads to irreversible neutralization of HIV. We confirmed our 
Considering that MPER antibodies even at high concen-
tration (100 µg/ml) did not induce shedding after short-term 
(1 h) preincubation (Fig. 3 B), whereas after 1-h preincuba-
tion, potent inhibition by the same mAbs can be seen in a 
conventional neutralization assay (Fig. 1), it was prudent to 
explore whether shedding is a mere artifact of the mAb’s in-
teraction with the virus or is intimately connected with the 
neutralization process. In conventional neutralization assays, 
antibody is present during the preincubation period and also 
during the entire infection process. Thus, for MPER antibod-
ies, for which an action after receptor engagement has been 
postulated (Cardoso et al., 2007; Frey et al., 2008, 2010; Alam 
et al., 2009), experimental conditions have to be chosen that 
allow discrimination between actions on the free virus and 
actions that occur in the context of virus–host cell interac-
tions. We thus performed neutralization experiments in which 
virus was only exposed to antibody during the preincubation 
Figure 3. MPER-specific antibodies induce gp120 shedding. (A) To assess exposure of gp41 epitopes upon neutralizing antibody treatment of viri-
ons, the capacity of antibody-treated JR-FL pseudovirus to bind to the gp41 cluster I mAb 3D6 was assessed. Virus was pretreated for 18 h with 10 µg/ml 
sCD4, 100 µg/ml 2F5, 100 µg/ml 4E10, or 10 µg/ml of the fusion inhibitor T-20 or left untreated (medium control). Virus was then captured onto 3D6-
coated ELISA plates and quantified by p24 ELISA. Error bars indicate SEM. One of three independent experiments is shown. (B) To assess gp120 shedding, 
JR-FL virus coexpressing mouse CD4 was pretreated with 10 µg/ml CD4-IgG2, 10 µg/ml b12, 100 µg/ml 2G12, 100 µg/ml 2F5, and 100 µg/ml 4E10 or left 
untreated for either 1 h or overnight (18–20 h). Virus was immobilized on anti-CD4–coated magnetic beads, and gp120 was quantified by ELISA. Percent 
gp120 shedding induced by the respective conditions in relation to mock-treated virus was determined. Data were normalized to p24 content (ELISA) to 
ensure that identical numbers of virions were assessed under each condition. Mean and SEM of three independent experiments are depicted. (C) Neutral-
ization activity against free virus was determined as depicted in the flow chart shown in Fig. S1. JR-FL pseudovirus was pretreated with serial dilutions of 
CD4-IgG2, b12, 2G12, 2F5, and 4E10 for either 1 or 16 h, with a maximal mAb concentration identical to the shedding assay shown in B. Virus was then 
bead immobilized, washed, and used to infect TZM-bl cells. In comparison, the entire preincubation mix without washing was transferred onto TZM-bl 
cells. In the latter case, 1-h preincubation corresponds to the conditions in a conventional neutralization assay, and 16-h preincubation corresponds to 
the long-term incubation depicted in Fig. 1. Percent neutralization induced by the respective conditions in relation to mock-treated virus was determined. 
Mean and SEM of two independent experiments are depicted.
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shedding from the probed R5, R5X4, and X4 isolates, dem-
onstrating that shedding of primary viruses is possible and 
may thus occur in vivo.
Is gp120 shedding a cause or a byproduct of antibody 
neutralization?
To probe whether gp120 shedding is mechanistically linked 
with the neutralization process or whether these two activ-
ities are independent, separable, or occur consecutively, we 
first defined the kinetics of the antibody-induced gp120 
shedding process in detailed time of addition experiments 
(Fig. 5 A). The loss of gp120 triggered by the probed mAbs 
proved to be strikingly different over the 33 h of monitoring. 
results by alternative experimental approaches: studying gp120 
shedding from virions using size-exclusion chromatography 
(Fig. 4 A) and shedding from envelope-expressing cells by 
Western blot and flow cytometry (Fig. 4, B and C; and Fig. S2). 
The same pattern of reactivity as in the bead-immobilized 
virion shedding assay was observed in these experiments: 
MPER mAbs and CD4bs-directed agents induced envelope 
dissociation, whereas 2G12 did not. To obtain insights into a 
potential physiological relevance of the shedding process, we 
verified our initial results (obtained with pseudovirus ex-
pressing the primary virus envelope JR-FL) with replication-
competent, PBMC-derived viruses (Fig. 4 D). As observed 
for pseudovirus, mAbs 2F5 and 4E10 induced potent gp120 
Figure 4. MPER antibodies induce gp120 shedding from virions and HIV envelope–expressing cells. (A) To analyze gp120 shedding by size- 
exclusion chromatography, JR-FL pseudovirus was treated with 25 µg/ml of CD4-IgG2, b12, 2G12, 2F5, 4E10, or total human IgG (huIgG) for 20–25 h. Samples 
were then separated on a Sephacryl S-1000 column, and collected fractions were analyzed for virion content and viral infectivity (relative light units 
[RLU] luciferase reporter production; relative light units are depicted in units of 3 × 103). One of three independent experiments is shown. (B) Shedding of 
gp120 from envelope-expressing cells was detected by Western blot analysis. 293-T cells expressing CT JR-FL gp160 were treated with 10 µg/ml CD4-
IgG2, 50 µg/ml 2G12, 50 µg/ml 2F5, or 50 µg/ml human IgG as control for the indicated time periods to allow for shedding. After cell lysis, total protein 
was separated by SDS-PAGE and analyzed by Western blotting for gp120 content. gp120 content was quantified by densitometric analysis, and shedding 
induced by neutralizing mAbs was expressed in relation to human IgG control. One of three independent experiments is shown. (C) 293-T cells that were 
mock transfected or transfected with CT JR-FL gp160 were treated with 10 µg/ml CD4-IgG2, 50 µg/ml 2F5, or 50 µg/ml human IgG as control for 20 h 
to allow for shedding. Cell surface–associated gp120 was detected by flow cytometry upon staining with biotinylated 2G12 and streptavidin-APC. One of 
three independent experiments is shown. (D) Induction of gp120 shedding from PBMC-derived, replication-competent HIV isolates was analyzed using 
PBMC-derived viruses JR-FL, DH123, and NL4-3. Coreceptor usage of viruses is indicated. Viruses were incubated with 10 µg/ml CD4-IgG2, 100 µg/ml 2F5, 
and 100 µg/ml 4E10 or left untreated for 24 h (mock control). The extent of gp120 shedding in mAb-treated samples was analyzed as described in Fig. 3 B.  
Data are expressed in relation to the mock control. Mean and SEM of three independent experiments are depicted.
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on virus infectivity upon short incubation (Fig. 1 F). Neu-
tralization activity therefore depended on interaction with 
the virus during the preincubation period and thus allowed 
direct assessment of the impact of shedding on the antibod-
ies’ neutralization activity. Strikingly, the timing of JR-FL 
neutralization and shedding was virtually identical for the 
two MPER antibodies, indicating that the process of shed-
ding is causally linked to their mechanism of neutralization. 
Although we cannot formally rule out that MPER binding 
itself confers neutralization in the absence of shedding, the 
kinetics of the processes were so closely related that, if these 
events were indeed functionally separable, shedding must oc-
cur very rapidly after JR-FL neutralization by MPER anti-
bodies. In contrast to MPER antibodies, no time-dependent 
association between shedding and neutralization of JR-FL 
pseudovirus was detected for b12. Although b12 induced 
shedding of 50% of JR-FL gp120 at concentrations >0.1 µg/ml 
(Fig. 5 B), lower concentrations (0.03 µg/ml; Fig. 6 A), 
which are perfectly capable of inducing neutralization, failed 
to induce potent gp120 shedding. The latter observation 
strongly suggests that the primary mechanism of b12 neu-
tralization is independent of shedding. Likewise, as shown 
above (Figs. 1 F, 3 B, and 5 A), 2G12 neutralized without in-
ducing gp120 shedding.
We next assessed the thermodynamic requirements of 
neutralization and shedding activity (Fig. 6 B) using mAb 
concentrations that 
yield 70% neutral-
ization after 20-h 
CD4-IgG2 provoked instant and almost complete shedding. 
2F5 and 4E10 reacted more rapidly than b12 and caused almost 
complete gp120 shedding upon long-term treatment, indicating 
that the antibodies must be able to release gp120 from both 
functional (trimeric) and nonfunctional envelope species 
(monomers and dimers) present on viral particles (Moore 
et al., 2006). Intriguingly, even after long-term incubation, 
b12 only achieved shedding of 58% of JR-FL gp120. The 
dose dependency of the b12 shedding process followed a 
similar pattern. gp120 shedding continuously increased in a 
dose-dependent manner for 2F5 and 4E10, whereas shedding 
by b12 plateaued at 50% and could not be augmented by 
increasing doses (Fig. 5 B). Determining precisely which 
functional properties of b12 shape its shedding activity will 
require further investigation. For instance, partial gp120 de-
pletion could result if mAb binding prompts shedding of 
neighboring units in a trimer (or dimer) but not of the unit 
the mAb is bound to. In general, differences in stoichiometric 
requirements, steric constraints, and mAb-induced conforma-
tional changes (Kwong et al., 2002) could be envisioned to 
cause the observed variable patterns of shedding activity 
among antibodies.
To explore whether the shedding process is an integral 
component of neutralization by individual antibodies, we 
monitored the kinetics of neutralization and shedding in par-
allel (Fig. 6 A). Each mAb was probed at a fixed antibody con-
centration that typically yields 70% neutralization of JR-FL 
pseudovirus after 20-h preincubation of mAb and virus at 
37°C but has (with the exception of 2G12) no notable effect 
Figure 5. Kinetics of neutralizing anti-
body-induced gp120 shedding. (A) Shed-
ding kinetics were determined over a 33-h 
time period. JR-FL pseudovirus was treated 
with fixed concentrations of CD4-IgG2  
(10 µg/ml), b12 (10 µg/ml), 2G12 (100 µg/ml), 
2F5 (100 µg/ml), and 4E10 (100 µg/ml) or left 
untreated (medium control) for the indicated 
time periods at 37°C, and gp120 shedding 
was assessed as described in Fig. 3 B. The rate 
of gp120 loss was fitted according to the 
formula L + (100  L) × exp(d × time).  
L denotes the maximal level of gp120 loss 
(lowest level of gp120) inflicted by the re-
spective antibody. The rate of gp120 loss is 
characterized by a constant d (units per 
hour). T1/2 max denotes the time until half 
maximal gp120 loss was reached. An overlay 
of five independent experiments is depicted. 
(B) The dose dependency of the shedding 
process was assessed by treating JR-FL pseu-
dovirus with increasing concentrations of 
b12, 2F5, and 4E10 or by leaving the pseudo-
virus untreated (medium control) for 22 h at 
37°C. Shedding was analyzed as described in 
Fig. 3 B. Data are expressed in relation to the 
medium control. Pooled data from three in-
dependent experiments are depicted. Curves 
depict sigmoid dose–dependent fits with 
variable slope and constraining upper limits 
at 100%. The dotted curves indicate the re-
spective 95% confidence intervals.
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Neutralizing antibodies induce gp120 shedding  
of genetically diverse viruses
Held together by labile, noncovalent intersubunit interactions 
between gp41 and gp120 (Finzi et al., 2010; Pancera et al., 
2010), the HIV envelope trimer is characterized by a high 
conformational diversity particularly within gp120, which is 
central to the envelope’s function in virus entry and immune 
evasion (Kwong et al., 2002; Chen et al., 2009). Notably, 
neutralization-sensitive HIV strains have been postulated to 
present envelope conformations, which, although optimized 
for receptor interaction, allow easier access for neutralizing 
antibodies and potentially destabilize the trimer (Park et al., 
2000; Pugach et al., 2004). These structural characteristics are 
also likely to steer the sensitivity of a given virus envelope to 
antibody-induced shedding. To address this, we first screened 
a panel of gp120- and gp41-specific antibodies for their shed-
ding activity against JR-FL pseudovirus (Fig. 7 A and Tables 
S2–S4). With the exception of 2G12, all mAbs that neutralized 
the virus also induced potent gp120 shedding. Particularly 
notable were the CD4bs-specific antibody 1F7 (Buchacher 
et al., 1994; Kunert et al., 1998) and the V3 loop antibody 447-
52D (Gorny et al., 1992), which achieved 96.3% and 87.6% 
shedding, respectively. Interestingly, the CD4bs antibody b6, 
which is known to bind predominantly nonfunctional enve-
lope forms (Poignard et al., 2003) and lacks neutralization 
activity against JR-FL, induced partial shedding (41.7%), 
demonstrating that both neutralizing and nonneutralizing anti-
bodies can participate in this process, presumably by acting 
against envelope monomers or dimers on the virion surface.
preincubation at 37°C. CD4-IgG2 potently neutralized vi-
rions and induced gp120 shedding even at low tempera-
tures. 2G12 displayed modest neutralization activity at 
19.4°C, which increased with temperature. Confirming our 
previous observations (Figs. 3 B and 4, A and B; and Figs. 5 A 
and 6 A), no notable shedding of JR-FL gp120 was induced 
by 2G12 at any of the probed temperatures. Antibodies b12, 
2F5, and 4E10 all required temperatures >28°C to neutral-
ize. Strikingly, MPER mAb neutralization and gp120 shed-
ding activity followed an identical temperature profile. 
Together with the observed close time-dependent synchro-
nization of their activities, these data provide strong evi-
dence that with the majority of isolates, MPER neutralization 
and shedding are indeed mechanistically linked. The ther-
modynamic processes observed for b12 were more com-
plex: although the chosen dose (0.03 µg/ml) induced potent 
neutralization at 37°C, which decreased in a temperature-
dependent manner, the same conditions induced only com-
paratively little shedding, particularly at lower temperatures. 
Although the pattern was similar (more shedding with 
higher temperature), neutralization by b12 was not obliga-
torily linked to shedding. Likewise, the high potency of b12 
to irreversibly neutralize HIV appears not to depend en-
tirely on the mAb’s shedding capacity, as complete irrevers-
ibility is achieved at antibody doses which only induce 
partial shedding (Figs. 2 and 5 B). The latter suggests that 
the degree of conformational fixation of gp120 inflicted 
upon b12 binding (Zhou et al., 2007) alone mediates irre-
versible inactivation.
Figure 6. Shedding and neutralization activity of MPER mAbs follow identical kinetics and thermodynamic requirements. (A) To compare the 
kinetics of shedding and neutralization, neutralization on TZM-bl cells and shedding activity (as described in Fig. 3 B) of JR-FL pseudovirus upon treat-
ment with mAbs b12 (0.03 µg/ml), 2G12 (12 µg/ml), 2F5 (2.5 µg/ml), and 4E10 (8.5 µg/ml) was assessed at the indicated times at 37°C. Chosen concentra-
tions correspond to 70% neutralization after 20-h incubation at 37°C. One of two independent experiments is depicted. (B) To compare thermodynamic 
requirements of shedding and neutralization, neutralization on TZM-bl cells and shedding activity (as described in Fig. 3 B) of JR-FL pseudovirus upon 
treatment with mAbs b12 (0.03 µg/ml), 2G12 (12 µg/ml), 2F5 (2.5 µg/ml), and 4E10 (8.5 µg/ml) for 20 h at the indicated temperature were assessed. One 
of three independent experiments is depicted. (A and B) Chosen concentrations correspond to 70% neutralization after 20-h incubation at 37°C.
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shedding in 11 of the 14 probed viruses. A comparatively low 
level of shedding (<30%) occurred with three viruses, WITO, 
TRO, and PVO.4, of which the latter two were not neutral-
ized by 2F5. The pattern for 4E10 was similar: neutralization 
was detected against all 14 viruses, against 13 of which shed-
ding activity was high. The only comparatively shedding-
insensitive virus (<30% shedding by 4E10), WITO, was 
nevertheless neutralized by 4E10. It is to be expected that 
both shedding efficacy and dependency of the MPER neu-
tralization process on shedding induction vary among diver-
gent virus strains, as the induction of gp120 shedding by sCD4 
also varies among virus strains (Moore et al., 1992; McDougal 
et al., 1996; Chertova et al., 2002). Besides epitope accessibil-
ity and antibody affinity, the conformational flexibility of 
gp120 and the stability of the noncovalent gp120/gp41 asso-
ciation of a specific virus strain will influence shedding effi-
cacy (Moore et al., 1992; Finzi et al., 2010; Pancera et al., 
2010). Thus, envelope trimers that can undergo the required 
To explore how ubiquitously neutralizing antibodies cause 
shedding across divergent strains, we assessed the shedding 
and neutralizing capacity of seven mAbs against a panel of 
14 pseudoviruses encompassing relatively easy to neutralize 
tier 1 and more resistant tier 2 and 3 isolates (Fig. 7 C and 
Tables S2–S4). The results confirmed our previous observa-
tions with the virus strain JR-FL (Fig. 7 A). mAbs directed to 
the CD4bs, V3 loop, and the MPER possessed potent shed-
ding activity against the majority of isolates. 2G12, which was 
ineffective in inducing shedding from JR-FL envelope–bearing 
virions, induced 30–60% shedding with 5 of the 14 probed 
viruses. Although clearly not a potent shedding inducer, 2G12 
can thus not be considered incapable of inducing shedding. 
mAb b12 promoted shedding of >30% in 8 of 14 viruses but 
had only marginal effects against the other 6 isolates, 3 of 
which were not neutralized by b12. The CD4i (CD4 in-
duced)-specific mAb 17b was largely ineffective in both, 
inducing neutralization and shedding. 2F5 induced potent 
Figure 7. Antibodies with gp120 shedding activity are commonly elicited in HIV infection. (A) Assessment of gp120 shedding activity induced 
by HIV envelope–specific mAbs. 20 µg/ml of mAbs directed to diverse epitopes in gp120 and gp41 (Table S3) were assessed for shedding activity (as de-
scribed in Fig. 3 B) after 20-h treatment of JR-FL pseudovirus at 37°C. Red bars denote mAbs that neutralize JR-FL, and gray bars denote nonneutralizing 
mAbs. Mean and SEM of three independent experiments are depicted. (B) Shedding activity elicited in HIV infection. 84 plasma samples derived from pa-
tients with chronic infection with the indicated HIV subtypes (Table S5) were probed for shedding (as described in Fig. 3 B), and neutralization activity was 
measured using TZM-bl cells against JR-FL (left) and NL4-3 pseudovirus (right) under identical preincubation conditions (20-h preincubation at 37°C). 
Correlation coefficient r (Pearson) and p-values are depicted. Data are means of two independent experiments. Dotted lines correspond to spontaneous 
gp120 shedding induced by healthy donor plasma (mean of three donors). (C) Shedding induced by a wide spectrum of mAbs with divergent specificities. 
Shedding (as described in Fig. 3 B) and neutralizing activity measured using TZM-bl cells of the indicated mAbs against 14 divergent viruses from tier 1–3 
(Tables S2–S4) were determined under identical preincubation conditions (10 µg/ml mAb and 20-h preincubation at 37°C). Correlation coefficient r (Pear-
son) and p-values are depicted. Significance was assessed after correcting for multiple testing (Bonferroni test). Data are means of two to four indepen-
dent experiments. Error bars indicate SEM. n.s., not significant.
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account for its high in vivo efficacy, particularly in established 
infection (Trkola et al., 2005; Hessell et al., 2009b).
In HIV vaccine development, a considerable effort has 
been directed toward eliciting neutralizing antibody responses 
that match the activities of the MPER-specific antibodies 
2F5 and 4E10, yet the molecular basis of their neutralization 
remained unresolved. Recently, protection by MPER-directed 
antibodies was suggested not to involve antibody-dependent 
cellular cytotoxicity, emphasizing the fact that neutralization 
rather than effector functions dominate the in vivo activity of 
these mAbs (Hessell et al., 2010). Our current findings under-
line the importance of the neutralization process to the 
MPER mAb antiviral activity. Here, we provide compelling 
evidence that neutralization by MPER mAbs involves induc-
tion of gp120 shedding, rendering virus inhibition irrevers-
ible. In our study, we explored the interaction of the antibodies 
with HIV before receptor engagement to obtain information 
explicitly on the virion-directed activity of the mAbs. Nota-
bly, as we show here, virion neutralization by MPER mAbs is 
a comparatively slow process that requires several hours. In 
the light of our findings, it will be interesting to verify the 
postulated action of MPER mAbs after receptor engagement 
and investigate the contribution of shedding in this process 
(Binley et al., 2003). MPER antibodies have been shown to 
preferentially bind to the prehairpin intermediate that forms 
upon receptor engagement (Cardoso et al., 2007; Frey et al., 
2008, 2010; Alam et al., 2009). Whether these confirmations 
are also adopted spontaneously in the absence of receptor en-
gagement or upon initial, low affinity interaction of MPER 
mAbs with the viral envelope remains to be determined. 
Be it upon receptor engagement or mAb interaction, gp120 
shedding can be envisioned to be closely associated with the 
formation of prehairpin intermediate.
Notably, our data only allow us to affirm a causal link be-
tween JR-FL virus neutralization and gp120 shedding by 
MPER antibodies within the temporal resolution of our assay 
systems. From this we can conclude that these actions are 
highly synchronized and follow identical kinetic, thermo-
dynamic, and stoichiometric requirements. Yet, this does not 
exclude that MPER mAb binding alone would suffice to 
neutralize the virus by blocking the refolding process of gp41 
and that shedding occurs as an immediate consequence of 
mAb binding. Whether a primary event leading to neutraliza-
tion or a consequence of neutralization, our data clearly indi-
cate that induction of gp120 shedding is closely associated 
with MPER antibody inhibition of the majority of HIV iso-
lates and needs to be factored into the mechanistic processes 
underlying HIV neutralization by MPER mAbs.
How can antibody binding principally lead to gp120 dis-
sociation from the envelope trimer? The HIV trimer association 
is relatively labile as it must support substantial conforma-
tional changes and dissociation of the gp120–gp41 heterodi-
mers during interaction with cellular receptors and fusion. 
In analogy to the entry process, conformational changes re-
sulting from antibody binding or conformational fixation by 
neutralizing antibodies can be envisioned to similarly disrupt 
conformational changes and tolerate neutralizing mAb bind-
ing without jeopardizing subunit association may be less 
prone to shed gp120 upon interaction with neutralizing anti-
bodies. However, overall, we found that shedding activity is 
prominently associated with neutralization activity. Of the 
probed neutralizing antibodies, MPER mAbs yielded the 
highest and broadest shedding activity overall. Particularly 
notable again were mAbs 447-52D and 1F7, which both in-
duced potent shedding that correlated with their neutraliza-
tion activity.
To obtain information on the frequency at which shed-
ding-inducing antibodies are elicited in HIV infection, we 
analyzed shedding and long-term neutralization activity in 84 
plasma samples derived from patients with chronic infection 
of subtypes A, B, C, CRF01_AE, and CFR02_AG (Fig. 7 B 
and Table S5). Cross-neutralizing activity against JR-FL was 
low in most plasma samples (reciprocal neutralization titer 
<100 in 38 of 84 samples) but was frequently associated with 
induction of shedding against the same virus. The low plasma 
neutralization titers against JR-FL did not allow firm conclu-
sions on a mechanistic link between JR-FL directed neutral-
ization and shedding activity to be drawn. In contrast, NL4-3 
was neutralized by a high proportion of isolates at relatively 
high titers (reciprocal neutralization titer >1,000 in 60 of 84 
samples). Shedding was induced by plasma of chronic patients 
across all subtypes and, in accordance with neutralization ac-
tivity, was higher against NL4-3 than JR-FL. Notably, the 
neutralization and shedding activity directed toward NL4-3 
were tightly correlated, further underlining a potential mech-
anistic association of these activities.
Conclusions
Although the ability of neutralizing antibodies to protect 
against HIV infection has been demonstrated in vivo (Mascola 
et al., 2000; Trkola et al., 2005; Hessell et al., 2009a), whether 
one or more actions, direct virus neutralization, induction of 
phagocytosis, inhibition of transfer (e.g., via DCs) to target 
cells, or killing of infected cells via antibody-dependent cel-
lular cytotoxicity, are key to block transmission is currently 
not known (Hessell et al., 2007; Huber and Trkola, 2007). 
Both gp120 shedding and antibody-induced conformational 
changes can lead to irreversible inactivation of HIV, which 
may positively influence in vivo efficacy of antibody neutral-
ization (McDougal et al., 1996; Poignard et al., 1996). The 
impact of antibodies mediating reversible neutralization may 
depend on rapid clearance of neutralized virions by phago-
cytes as influences of the milieu (e.g., migration to anatomical 
sites with lower antibody concentration; engulfment by DCs) 
may lead to antibody dissociation and reconstitute the virus’s 
infectivity. Neutralizing antibodies that irrevocably sterilize 
virions before target cells are encountered would in these sce-
narios be of clear benefit. However, failure to irreversibly 
neutralize does not necessarily render an antibody ineffective 
in vivo. Although reversible, 2G12 neutralization occurs, as 
we show in this study, more rapidly than neutralization with 
b12, 2F5, and 4E10, and its immediate action may indeed 
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study, a variety of neutralizing antibodies induce shedding and 
thus irreversibly neutralize HIV. Thus, elicitation of antibodies 
that irreversibly neutralize should be within reach, and it will 
certainly be of interest to assess the recently identified potently 
neutralizing antibodies PG9, PG16, HJ16, and VRC01 for their 
capacity to irreversibly neutralize HIV (Walker et al., 2009; 
Corti et al., 2010; Pietzsch et al., 2010; Wu et al., 2010). A com-
bination of antibodies that act rapidly and neutralize irreversibly 
may prove to be advantageous. Intriguingly, 2G12, which lacks 
the capacity to irreversibly neutralize but instead rapidly binds 
to and neutralizes HIV, effectively blocks the virus in vivo, as 
passive immunization trials with combinations of 2G12, 2F5, 
and 4E10 confirmed (Trkola et al., 2005; Mehandru et al., 2007). 
Although only 2G12 was assumed to be effective in these trials 
based on escape virus formation, a matter for speculation re-
mains whether in vivo efficacy may have in part resulted from a 
rapid but reversible inhibition by 2G12 followed by sustained, 
irreversible inhibition by the MPER antibodies.
Although commonly low titered and often subneutraliz-
ing in vitro, neutralizing antibody concentrations in mucosal 
fluids nevertheless protected against SHIV transmission in 
challenge studies (Mascola et al., 2000; Hessell et al., 2009b). 
Our data provide a possible mechanistic basis for these observa-
tions as we demonstrate that upon long-term contact, efficient 
(and in most cases irreversible) inactivation of HIV occurs 
at comparatively low antibody concentrations. Although the 
precise delineation of the molecular processes that induce 
gp120 shedding upon MPER mAb binding will require further 
investigation, our current observations reveal important as-
pects of these antibodies’ mode of action and lay a foundation 
for the design of vaccines and compounds that induce gp120 
shedding and irreversible inactivation in a similar manner.
MATERIALS AND METHODS
Reagents and clinical specimens. Antibodies used in this study were 
made available by D. Burton (The Scripps Research Institute, La Jolla, CA), 
D. Katinger and H. Katinger (Polymun Scientific, Vienna, Austria), J. Robin-
son (Tulane University Medical Center, New Orleans, LA), S. Zolla-Pazner 
(New York University School of Medicine, New York, NY), and the AIDS 
Research and Reference Reagent Program (Division of AIDS, National In-
stitute of Allergy and Infectious Diseases, National Institutes of Health). The 
precise origin and epitope specificities of monoclonal antibodies used in this 
study are listed in Table S3. Tetrameric CD4-Ig (CD4-IgG2; Allaway et al., 
1995) and sCD4 (Deen et al., 1988) were provided by W. Olson (Progenics 
Pharmaceuticals, Tarrytown, NY); T-20 (Kilby et al., 1998) was provided by 
Roche. Human IgG was purchased from Sigma-Aldrich. Plasma samples 
were obtained from individuals with chronic HIV-1 infection (>6 mo in-
fected) enrolled in (a) the Swiss HIV Cohort Study (Schoeni-Affolter et al., 
2010), (b) the Zurich Primary HIV infection study (Huber et al., 2006), and 
(c) the Swiss Spanish Treatment Interruption trial (Trkola et al., 2004). All 
experiments were approved by the local ethics committee of the University 
Hospital Zurich, and written informed consent was obtained from all indi-
viduals. Detailed patient demographics are listed in Table S5.
Cells. 293-T and TZM-bl cells were obtained from the American Type Cul-
ture Collection and the National Institutes of Health AIDS repository, re-
spectively, and cultured as described previously (Rusert et al., 2009).
Virus preparation. Envelope-pseudotyped virus was prepared as previously 
described (Rusert et al., 2009). For generation of envelope-pseudotyped virus 
the fragile inter- and intrasubunit associations. It can be spec-
ulated that the trimer association may depend on a certain 
degree of flexibility of all three subunits to allow synchronized 
movements. Once one unit’s conformation is arrested, for ex-
ample by mAb binding to the MPER domain and the viral 
membrane, trimer association may be jeopardized. Alternatively, 
envelope conformations that expose the MPER and enable 
2F5 and 4E10 binding may induce instability of the trimer. 
The strength of the subunit interaction as well as the degree 
by which conformational changes are inflicted will likely de-
termine whether and to what extent shedding is associated 
with the neutralization process of a given virus antibody 
combination. Related observations have been made in other 
virus infections in which envelope or capsid conformation 
changes need to occur before or during neutralization (Witz 
and Brown, 2001; Selinka et al., 2003; Lok et al., 2008).
A principle question remains: is induction of shedding by 
neutralizing antibodies of physiological relevance? Clearly it 
is no prerequisite of neutralization as 2G12 and b12, which 
both can neutralize without inducing shedding, have proven 
in vivo efficacy (Trkola et al., 2005; Hessell et al., 2007, 2009b; 
Mehandru et al., 2007) Likewise, the in vitro and in vivo 
action of sCD4 has been suggested to be dominated by recep-
tor binding site occupancy rather than by induction of gp120 
shedding (Moore et al., 1990, 1992; McKeating et al., 1991; 
Orloff et al., 1993; McDougal et al., 1996; Haim et al., 2009). 
Yet, we would argue that the capacity of neutralizing antibod-
ies to induce shedding or otherwise irreversibly neutralize 
HIV could be expected to substantially impact their in vivo 
activity. Virus transmission across mucosal surfaces is an ineffi-
cient process, and only few founder viruses establish the new 
infection (Salazar-Gonzalez et al., 2009). Mucus and epithelia 
trap virus, physically restricting transmission, and the limited 
number of transmitted virions depend on locating appropri-
ate target cells (Haase, 2010). These processes require time 
during which virions remain vulnerable to antibody attack. 
During established infection, the bulk of HIV particles in the 
periphery are rapidly turned over with an estimated half-life 
of plasma virus of 28–110 min (Ramratnam et al., 1999). If 
this turnover is to be influenced by neutralizing antibodies, it 
requires a more rapid action than MPER antibodies appear 
capable of. Yet, not all virions are in the periphery and cleared. 
HIV is known to be trapped in various tissue compartments 
(e.g., by immature and mature DCs, follicular DCs, and B cells) 
where virions can be retained in an infectious state for pro-
longed time periods (Moir et al., 2000; Turville et al., 2004; 
Bánki et al., 2005; Ho et al., 2007; Yu et al., 2008). Although 
encompassing only a small fraction of the circulating virions, 
these trapped HIV particles are thought to contribute sub-
stantially toward dissemination and the formation of a viral 
reservoir in the infected individual. In this setting, antibodies 
that irreversibly neutralize the virus could indeed be of clear 
benefit, and antibody activities that require prolonged inter-
action with the virus may come in play.
Should vaccine-elicited antibody responses be specifically 
tailored to induce irreversible neutralization? As we show in this 
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Detection of gp120 shedding from bead immobilized virus by 
ELISA. (a) Pseudovirus expressing mouse CD4 on the viral surface was in-
cubated at the indicated time/temperature conditions in the presence or ab-
sence of neutralizing antibodies. Virus was then immobilized onto magnetic 
beads coated with rat anti–mouse CD4 antibodies (Invitrogen) and washed 
with TBS/2% BSA using a magnetic 96-well plate (OZ Biosciences) to sepa-
rate virus from unbound antibodies and shed gp120. Finally, the magnetic 
pellets containing washed virus were lysed in TBS containing 1% Empigen 
and gp120, and the p24 content of the lysate was quantified by ELISA. The 
percentage of gp120 shedding induced by the respective conditions is depen-
dent on the experiment, expressed either in relation to the original virus 
stock (decay experiments; Figs. 5 A and 6 A) or in relation to mock-treated 
virus controls (all other results). Mock-treated virus controls correspond to 
0% shedding and 100% gp120 content. (b) Analysis of gp120 from PBMC-
derived, replication-competent virus was essentially identical. The only dif-
ference in this set up was that virus was immobilized on magnetic anti-CD44 
beads (Miltenyi Biotec) for 1 h at 4°C and washed on µMACS columns. 
Purified virus was eluted in TBS/1% Empigen and gp120, and the p24 con-
tent of the lysate was quantified by ELISA.
Detection of gp120 shedding by gel filtration. Size-exclusion chroma-
tography was performed as described previously (Moore et al., 1990). In 
brief, JR-FL–envelope-pseudotyped virions were concentrated by ultracen-
trifugation over a 32% sucrose cushion in a centrifuge (Centrikon Ultra, 
Rotor TST 28.38; Kontron Instruments) at 28,000 rpm for 2 h. Aliquots of 
the concentrated virus (100 ng p24) were treated with 25 µg/ml CD4-IgG2, 
25 µg/ml b12, 25 µg/ml 2G12, 25 µg/ml 2F5, and 25 µg/ml 4E10 or 25 µg/ml 
human IgG for 20–25 h. Samples were then subjected to size-exclusion 
chromatography using a (10 ml, 16/50) Sephacryl S-1000 column (GE 
Healthcare) on a purifier system (AEKTA; GE Healthcare). 200-µl fractions 
were collected and analyzed for p24 and gp120 content by ELISA, and infec-
tivity was probed on TZM-bl reporter cells.
Detection of gp120 shedding by Western blot analysis. 293T cells 
were transfected in 24-well plates with CT JR-FL gp160, a cytosolic tail 
truncated gp160 construct known to yield higher envelope trimer expression 
(Binley et al., 2003), and pCMV-rev (Lewis et al., 1990) using jetPEI (Poly-
plus Transfection) according to the manufacturer’s instruction. As mock con-
trol, empty pcDNA3.1 vector was cotransfected together with pCMV-rev 
under identical conditions. 20 or 1 h before harvest, the cells were treated 
with 50 µg/ml total human IgG, 10 µg/ml CD4-IgG2, 50 µg/ml 2G12, or 
50 µg/ml 2F5. Cells were then washed to remove shed gp120 in PBS/10 mM 
EDTA and lysed with 100 µl of 50 mM Tris, 150 mM NaCl, SDS 0.1% (wt/
vol), 0.5% (wt/vol) Na deoxycholate, and 1% Triton X-100, pH 7.4 (RIPA 
buffer). The cell lysates were analyzed on a NuPAGE 4–12% gradient gel 
(Invitrogen) and subsequently blotted onto a Hybond C membrane (GE 
Healthcare) and analyzed for gp120 content using goat anti-gp120 antibody 
(D7324; Aalto) and horseradish peroxidase–conjugated rabbit anti–goat IgG 
and detection with ECL (GE Healthcare). Imaging analysis was performed 
using the LAS4000 imaging system (Fujifilm), and densitometry was per-
formed using Multi Gauge version 3.0 software (Fujifilm). All data were nor-
malized to uncleaved (intracellular) gp160 of the respective sample to correct 
for potential differences in transfection efficiency.
Detection of gp120 shedding by FACS. 293-T cells expressing CT 
JR-FL gp160 and controls were prepared as described for the analysis of 
gp120 shedding by Western blot. 20 h before harvest, the culture medium was 
exchanged for fresh medium containing protein transport inhibitor Brefeldin A 
(BioLegend) at 1:1,000 to limit incorporation of new trimer molecules in 
the cell membrane during the following shedding analysis. Cells were then 
incubated for 1 or 20 h with total human 50 µg/ml IgG, 10 µg/ml CD4-IgG2, 
or 50 µg/ml 2F5, after which cells were detached from plates with PBS/10 mM 
EDTA (Invitrogen) and washed twice with PBS, 1% FCS, and 2 mM EDTA. 
The level of residual surface gp120 was determined by flow cytometry upon 
staining with biotinylated 2G12 and detection by streptavidin-APC (BioLegend). 
with mouse CD4 on the viral surface, 30 µg of mouse CD4 plasmid (mCD4-
pCMV-SPORT6, IRAVp968B1245D; RZPD Deutsches Ressourcenzen-
trum für Genomforschung GmbH) was cotransfected with 7.5 µg of envelope 
expression plasmid, 22.5 µg of the envelope-deficient HIV-1 backbone vector 
pNL-luc-AM, and 120 µg polyethylenimine. Stocks of replication-competent 
virus were prepared as described previously (Rusert et al., 2005).
Neutralization assay using envelope-pseudotyped virus. The neutral-
ization activity of mAbs and patient plasma was evaluated on TZM-bl cells 
essentially as described previously (Rusert et al., 2009). Virus input was cho-
sen to yield comparable reporter gene production (10,000–20,000 relative 
light units) in untreated control samples across divergent viruses. The anti-
body concentrations causing 50% reduction in viral infectivity (IC50) were 
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